Alan List, MD, is a hematologist and physician-scientist who is recognized for his many contributions in the development of more effective treatment strategies for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). He is the author of more than 450 peer-reviewed manuscripts, chapters, and books, and is the former President and CEO of Moffitt Cancer Center, as well as past president of the Society of Hematologic Oncology (2017–18). His work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with deletion 5q MDS. Dr. List was also a key leader in the development and FDA approval of two other agents for MDS, i.e., azacitidine (Vidaza®) and, most recently, luspatercept (Reblozyl®). His laboratory investigations identified a previously unrecognized form of programmed cell death termed pyroptosis, driving the pathobiology of MDS.

Dr. List is a Charter Fellow in the National Academy of Inventors, an inductee into the Florida Inventors Hall of Fame, and holds 18 U.S. patents with more than 50 applications filed. He is the recipient of the Celgene 2016 Career Achievement Award for Clinical Research in Hematology, the General Motors Cancer Research Foundation Merit Award, the J.P. McCarthy Foundation International Prize, the Emil J. Freireich Award, a Joshua Lederberg Society Fellow, and the Aplastic Anemia & MDS International Foundation Leadership in Science Award.